273 related articles for article (PubMed ID: 26661208)
1. The potassium channel KCa3.1 constitutes a pharmacological target for neuroinflammation associated with ischemia/reperfusion stroke.
Chen YJ; Nguyen HM; Maezawa I; Grössinger EM; Garing AL; Köhler R; Jin LW; Wulff H
J Cereb Blood Flow Metab; 2016 Dec; 36(12):2146-2161. PubMed ID: 26661208
[TBL] [Abstract][Full Text] [Related]
2. The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke.
Chen YJ; Raman G; Bodendiek S; O'Donnell ME; Wulff H
J Cereb Blood Flow Metab; 2011 Dec; 31(12):2363-74. PubMed ID: 21750563
[TBL] [Abstract][Full Text] [Related]
3. The potassium channel KCa3.1 constitutes a pharmacological target for astrogliosis associated with ischemia stroke.
Yi M; Wei T; Wang Y; Lu Q; Chen G; Gao X; Geller HM; Chen H; Yu Z
J Neuroinflammation; 2017 Oct; 14(1):203. PubMed ID: 29037241
[TBL] [Abstract][Full Text] [Related]
4. Repurposing the K
Lee RD; Chen YJ; Nguyen HM; Singh L; Dietrich CJ; Pyles BR; Cui Y; Weinstein JR; Wulff H
Transl Stroke Res; 2024 Jun; 15(3):518-532. PubMed ID: 37088858
[TBL] [Abstract][Full Text] [Related]
5. Blood-brain barrier KCa3.1 channels: evidence for a role in brain Na uptake and edema in ischemic stroke.
Chen YJ; Wallace BK; Yuen N; Jenkins DP; Wulff H; O'Donnell ME
Stroke; 2015 Jan; 46(1):237-44. PubMed ID: 25477223
[TBL] [Abstract][Full Text] [Related]
6. Differential Kv1.3, KCa3.1, and Kir2.1 expression in "classically" and "alternatively" activated microglia.
Nguyen HM; Grössinger EM; Horiuchi M; Davis KW; Jin LW; Maezawa I; Wulff H
Glia; 2017 Jan; 65(1):106-121. PubMed ID: 27696527
[TBL] [Abstract][Full Text] [Related]
7. Targeting of microglial KCa3.1 channels by TRAM-34 exacerbates hippocampal neurodegeneration and does not affect ictogenesis and epileptogenesis in chronic temporal lobe epilepsy models.
Ongerth T; Russmann V; Fischborn S; Boes K; Siegl C; Potschka H
Eur J Pharmacol; 2014 Oct; 740():72-80. PubMed ID: 25016931
[TBL] [Abstract][Full Text] [Related]
8. KCa3.1 constitutes a pharmacological target for astrogliosis associated with Alzheimer's disease.
Yi M; Yu P; Lu Q; Geller HM; Yu Z; Chen H
Mol Cell Neurosci; 2016 Oct; 76():21-32. PubMed ID: 27567685
[TBL] [Abstract][Full Text] [Related]
9. KCa3.1 inhibition switches the phenotype of glioma-infiltrating microglia/macrophages.
Grimaldi A; D'Alessandro G; Golia MT; Grössinger EM; Di Angelantonio S; Ragozzino D; Santoro A; Esposito V; Wulff H; Catalano M; Limatola C
Cell Death Dis; 2016 Apr; 7(4):e2174. PubMed ID: 27054329
[TBL] [Abstract][Full Text] [Related]
10. Temporal profiling of Kv1.3 channel expression in brain mononuclear phagocytes following ischemic stroke.
Gao T; Raza SA; Ramesha S; Nwabueze NV; Tomkins AJ; Cheng L; Xiao H; Yepes M; Rangaraju S
J Neuroinflammation; 2019 Jun; 16(1):116. PubMed ID: 31153377
[TBL] [Abstract][Full Text] [Related]
11. The potassium channel KCa3.1 as new therapeutic target for the prevention of obliterative airway disease.
Hua X; Deuse T; Chen YJ; Wulff H; Stubbendorff M; Köhler R; Miura H; Länger F; Reichenspurner H; Robbins RC; Schrepfer S
Transplantation; 2013 Jan; 95(2):285-92. PubMed ID: 23325003
[TBL] [Abstract][Full Text] [Related]
12. KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment.
D'Alessandro G; Grimaldi A; Chece G; Porzia A; Esposito V; Santoro A; Salvati M; Mainiero F; Ragozzino D; Di Angelantonio S; Wulff H; Catalano M; Limatola C
Oncotarget; 2016 May; 7(21):30781-96. PubMed ID: 27096953
[TBL] [Abstract][Full Text] [Related]
13. Blockade of KCa3.1 potassium channels protects against cisplatin-induced acute kidney injury.
Chen CL; Liao JW; Hu OY; Pao LH
Arch Toxicol; 2016 Sep; 90(9):2249-2260. PubMed ID: 26438401
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the potassium channel Kv1.3 reduces infarction and inflammation in ischemic stroke.
Chen YJ; Nguyen HM; Maezawa I; Jin LW; Wulff H
Ann Clin Transl Neurol; 2018 Feb; 5(2):147-161. PubMed ID: 29468176
[TBL] [Abstract][Full Text] [Related]
15. Senicapoc: Repurposing a Drug to Target Microglia K
Staal RGW; Weinstein JR; Nattini M; Cajina M; Chandresana G; Möller T
Neurochem Res; 2017 Sep; 42(9):2639-2645. PubMed ID: 28364331
[TBL] [Abstract][Full Text] [Related]
16. Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease.
Jin LW; Lucente JD; Nguyen HM; Singh V; Singh L; Chavez M; Bushong T; Wulff H; Maezawa I
Ann Clin Transl Neurol; 2019 Apr; 6(4):723-738. PubMed ID: 31019997
[TBL] [Abstract][Full Text] [Related]
17. KCa3.1 channels are involved in the infiltrative behavior of glioblastoma in vivo.
D'Alessandro G; Catalano M; Sciaccaluga M; Chece G; Cipriani R; Rosito M; Grimaldi A; Lauro C; Cantore G; Santoro A; Fioretti B; Franciolini F; Wulff H; Limatola C
Cell Death Dis; 2013 Aug; 4(8):e773. PubMed ID: 23949222
[TBL] [Abstract][Full Text] [Related]
18. Blockade of KCa3.1 Attenuates Left Ventricular Remodeling after Experimental Myocardial Infarction.
Ju CH; Wang XP; Gao CY; Zhang SX; Ma XH; Liu C
Cell Physiol Biochem; 2015; 36(4):1305-15. PubMed ID: 26160442
[TBL] [Abstract][Full Text] [Related]
19. Activation of the KCa3.1 channel contributes to traumatic scratch injury-induced reactive astrogliosis through the JNK/c-Jun signaling pathway.
Yi M; Dou F; Lu Q; Yu Z; Chen H
Neurosci Lett; 2016 Jun; 624():62-71. PubMed ID: 27163196
[TBL] [Abstract][Full Text] [Related]
20. Ca2+ -activated K+ channel-3.1 blocker TRAM-34 alleviates murine allergic rhinitis.
Lin H; Zheng C; Li J; Yang C; Hu L
Int Immunopharmacol; 2014 Dec; 23(2):642-8. PubMed ID: 25466273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
